311P - Circulating cytokines in the differential diagnosis of endometrial cancer

Background

Endometrial cancer (EC) is the most common gynecological malignancy worldwide. Therefore, early diagnosis of EC is critical. Routine endometrial cytology has low sensitivity and specificity. If there are few endometrial cells and there are no obvious signs of atypia, knowledge of additional diagnostic criteria will help identify pathological processes in the endometrium. The aim of the study was to evaluate the diagnostic significance of serum cytokines in patients with EC and uterine myoma (UM).

Methods

The blood serum of primary patients with stage I (initial) EC (n=42) according to FIGO was studied. The mean age of patients was 37-77 years, and patients with UM (n=20) (41-59 years). The control group included 30 practically healthy female donors (23-65 years). The level of IL1RA, IL17A (Cytokin, Russia), IL1β, 2, 4, 6, 8, 10, 18, TNFα, IFNγ and MCP- 1 (VBV, Russia) in pg/ml. The results were expressed as IQRQ1-Q3. The study was carried out in accordance with the requirements of the Ethics Commission of the Institute of ME&PhC of UlSU. Statistical analysis was performed using Jamovi 1.6.5.0.

Results

A significant increase in the level of IL1RA in the blood serum of patients at stage I EC at UM (p=0.002) and relative to control (p=0.001). The concentration of circulating IL6 was significantly increased at initial EC compared with UM (p=0.044). MCP-1 in the serum of patients with UM is reduced compared with the control group (p=0.013). At stage I EC, the level of MCP-1 in serum is significantly higher compared with control (p=0.012) and UM (p=0.005). The levels of other cytokines did not show significant differences with the control group in the presented model. In a univariate logistic regression analysis for the differential diagnosis between UM and EC, statistical significance was jointly demonstrated by IL1RA and serum IL6/MCP-1 The risk of EC increases with concomitantly elevated serum levels of IL1RA and IL6 (R2=0.82, χ²=30.5, p=0.001) with a probability of 96.2% (Spec.=0.80, Sens.=0.96), as well as with simultaneously elevated levels of IL1RA and MCP-1 (R2=0.75, χ²=26.4, р=0.001) with 88.5% probability (Spec.=0.80, Sens.=0.88).

Conclusions

Evaluation of the serum level of IL1RA, IL6, MCP-1 can be used in the differential diagnosis of EC and UM.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.